Navigation Links
Cardica Announces Fiscal 2010 First Quarter Financial Results and Business Progress

REDWOOD CITY, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Cardica, Inc. (Nasdaq: CRDC) today reported financial results for its fiscal 2010 first quarter ended September 30, 2009. Our financial results reflect a transition of our sales model related to our automated anastomotic systems used by cardiac surgeons to perform coronary bypass surgery and the expansion of our business through the development of an endoscopic microcutter intended for use by general, thoracic, gynecologic, bariatric and urologic surgeons.

"During the first quarter of fiscal 2010, we signed six new agreements with independent distributors and manufacturers' representatives, bringing our external sales team to 22. We utilized the summer months, during which typically there are fewer cardiac surgery procedures, to train our new sales representatives, preparing them to proctor bypass procedures using our automated anastomosis products moving forward. While our revised sales model using a core sales team supported by independent distributors and manufacturers' representatives remains to be proven, we believe that it will allow us to incrementally increase clinician adoption of our cardiac surgery products while controlling our costs," said Bernard A. Hausen, M.D., Ph.D., president and chief executive officer of Cardica.

"In addition, we completed a private placement that provided funding for the further development of the Cardica Microcutter, which applies our proprietary automated stapling technology outside of cardiac surgery and has potential use in a range of surgical applications, including bariatric, thoracic and general surgery. We continue to make strides in the development of our microcutter, and we intend to initiate animal testing in the first half of calendar 2010."

Recent Highlights and Accomplishments

  • Increased cumulative worldwide shipments of PAS-Port® Proximal Anastomosis Systems to over 16,100 units, with a total of 1,186 units sold in the first quarter of fiscal 2010;
  • Increased cumulative worldwide shipments of C-Port® Distal Anastomosis Systems to over 9,500 units, with a total of 181 units sold in the first quarter of fiscal 2010;
  • Expanded network of independent distributors and manufacturers' representatives through the addition of six organizations: AlphaCor, Bio Instruments, Ilex Medical, Medical Dynamics, MEDI-MAC Cardiovascular and MedSurg Specialty Medical;
  • Raised $10 million in net proceeds through the sale of 8,142,082 shares of common stock and warrants to purchase 4,071,046 shares of common stock; and
  • Continued development of the Cardica Microcutter, a multi-fire endolinear microcutter device based on Cardica's proprietary "staple-on-a-strip" technology.

Fiscal 2010 First Quarter Financial Results

Net product sales totaled $0.8 million for the fiscal 2010 first quarter, compared to $1.6 million for the fiscal 2009 first quarter. Net product sales decreased as a result of Cardica's smaller direct sales force and the transition period necessary to train our new independent distributors and manufacturers' representatives and due to the lower number of cardiac surgery bypass procedures in the summer months of July and August. Total net revenue was $0.9 million for the fiscal 2010 first quarter, compared to $2.1 million for the same period of fiscal 2009. Cost of product sales decreased to $0.8 million for the fiscal 2010 first quarter, compared to $1.1 million in the fiscal 2009 first quarter.

For the fiscal 2010 first quarter, research and development expenses decreased to $1.1 million, compared to $2.3 million for the fiscal 2009 first quarter. Selling, general and administrative expenses for the fiscal 2010 first quarter decreased to $1.6 million, compared to $3.9 million for the fiscal 2009 first quarter. The lower expenses are due to the actions taken in fiscal 2009 to change our sales approach to a more variable cost model and to lower our headcount.

The net loss for the fiscal 2010 first quarter decreased to $2.7 million, or $0.17 per share, compared to a net loss of $5.2 million, or $0.33 per share, for the fiscal 2009 first quarter.

Cash and cash equivalents at September 30, 2009 were $13.3 million, which included $10.0 million in net proceeds from a private placement completed on September 30, 2009. Total cash and cash equivalents as of June 30, 2009 were $5.3 million. As of September 30, 2009, Cardica had approximately 24 million common shares outstanding.

Financial Guidance for Fiscal 2010

Cardica continues to be in a transition period for its cardiac surgery business and is not able to provide product sales guidance for fiscal 2010. For fiscal 2010, Cardica continues to expect that research and development and selling, general and administrative expenses will total between $11 and $13 million, including non-cash stock-based compensation expense of approximately $1.5 million. Cardica continues to expect its cash and cash equivalents to decline by approximately $2.5 million per quarter in fiscal 2010, without giving effect to any additional financing transactions.

Conference Call Details

Cardica's management will host a conference call today, October 29, 2009, at 4:30 p.m. Eastern Time to discuss Cardica's financial results and provide a business update. To access the live call, please dial 866-713-8562 from the United States and Canada or 617-597-5310 internationally. The conference ID is 91147635. Please dial in approximately 10 minutes prior to the start of the call. A telephone replay will be available beginning approximately one hour after the call through November 5, 2009, and may be accessed by dialing 888-286-8010 from the United States and Canada or 617-801-6888 internationally. The replay passcode is 59062423.

To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of Cardica's website at Please connect to the website at least 15 minutes prior to the call to allow for any necessary software downloads.

The webcast is also being distributed through the Thomson StreetEvents Network. Individual investors can listen to the call at, Thomson's individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents at, a password-protected event management site.

About Cardica

Cardica is a leading provider of automated anastomosis systems for coronary artery bypass graft (CABG) surgery. By replacing hand-sewn sutures with easy-to-use automated systems, Cardica's products provide cardiovascular surgeons with rapid, reliable and consistently reproducible anastomoses, or connections of blood vessels, often considered the most critical aspect of the CABG procedure. Cardica's C-Port(R) Distal Anastomosis Systems are marketed in the United States and Europe and its PAS-Port(R) Proximal Anastomosis System is marketed in the United States, Europe and Japan. In addition, the company is developing the Cardica Microcutter, a true multi-fire endoscopic stapling device designed to be used in a variety of settings, including bariatric, thoracic and general surgery.

Forward-Looking Statements

This press release contains "forward-looking" statements, including all statements regarding further clinical adoption and future sales of Cardica's automated anastomosis products, the future development and commercial potential of the Cardica Microcutter, the sufficiency of Cardica's capital resources and the matters described under the heading "Financial Guidance for Fiscal 2010." Any statements contained in this press release that are not historical facts may be deemed to be forward-looking statements. The words "potential," "will," "believe," "expect," "intend" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause Cardica's results to differ materially from those indicated by these forward-looking statements, including that Cardica's current and any future products may never gain any significant degree of market acceptance; that Cardica may not be successful in its efforts to develop the Cardica Microcutter and expand its product portfolio; that any future Cardica products face development, regulatory, reimbursement and manufacturing risks; that Cardica's intellectual property rights may not provide adequate protection; that Cardica's sales, marketing and distribution strategy and capabilities may not be sufficient or successful; and that recent workforce reductions and general business and economic conditions may impair Cardica's ability to market and develop products, as well as other risks detailed from time to time in Cardica's reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended June 30, 2009. Cardica expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein. You are encouraged to read Cardica's reports filed with the U.S. Securities and Exchange Commission, available at

                            Cardica, Inc.
                       Statements of Operations
           (amounts in thousands except per share amounts)

                                            Three months ended
                                               September 30,
                                            2009          2008
                                            ----          ----
      Product sales, net                    $817        $1,560
       revenue                               105           523
      Royalty revenue                         25            23
                                              --            --
        Total                                947         2,106

    Operating costs and expenses
      Cost of product
       sales                                 840         1,110
      Research and
       development                         1,143         2,325
      Selling, general
       administrative                      1,604         3,892
                                           -----         -----
        Total operating
         costs and
         expenses                          3,587         7,327
                                           -----         -----

    Loss from operations                  (2,640)       (5,221)
    Interest and other
     income                                    6            97
    Interest expense                         (30)          (30)

                                         -------       -------
    Net loss                             $(2,664)      $(5,154)
                                         =======       =======

    Basic and diluted
     net loss per share                   $(0.17)       $(0.33)
                                          ======        ======

    Shares used in computing basic and
     diluted net loss per share           15,796        15,741
                                          ======        ======

                             Balance Sheets
                        (amounts in thousands)

                                        September 30,    June 30,
                                            2009          2009
                                            ----          ----
    Assets                                     (unaudited)
      Cash and cash equivalents          $13,337        $5,328
      Accounts receivable                    322           624
      Inventories                          1,889         1,895
      Other assets                         2,437         2,493
                                           -----         -----
        Total assets                     $17,985       $10,340
                                         =======       =======

    Liabilities and stockholders'
      Accounts payable and other
       liabilities                       $1,353        $1,551
      Short term debt                      2,000         2,000
      Deferred revenue                       422           527
      Stockholders' equity                14,210         6,262
                                          ------         -----
        Total liabilities and
         stockholders' equity            $17,985       $10,340
                                         =======       =======

SOURCE Cardica, Inc.

SOURCE Cardica, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Cardica Reports Positive Top-Line Results and Submits 510(k) for PAS-Port(R) Proximal Anastomosis System in Cardiac Bypass Surgery
2. Cardica to Host Investor Briefing on Revolutionizing Revascularization
3. Cardica Announces Publication of Pivotal PAS-Port(R) Proximal Anastomosis System Clinical Trial Results
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
(Date:11/27/2015)... , Pays-Bas, November 27, 2015 ... l,immunothérapie au traitement photodynamique au Bremachlorin contre le ... nouvelle approche consistant à combiner l,immunothérapie au traitement ...    --> Une nouvelle approche ... Bremachlorin contre le cancer avancé.    ...
(Date:11/27/2015)... NEW YORK , November 27, 2015 ... health system is set to go online. The potential ... and processes is vast and far from fully exploited ... access to patient health records, either via mobile tablet ... ) --> ) ...
(Date:11/27/2015)... UTRECHT , Niederlande, November 27, 2015 /PRNewswire/ ... mit fotodynamischer Bremachlorin-Therapie bei fortgeschrittenem Krebs.   ... fotodynamischer Bremachlorin-Therapie bei fortgeschrittenem Krebs.   --> ... fotodynamischer Bremachlorin-Therapie bei fortgeschrittenem Krebs.   ... berichtet. --> Clinical Cancer Research ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... According to an ... 2015 American Dental Association meeting in Washington D.C. revolved around the fact that proper ... overall health. The talk stressed the link between periodontal disease (more commonly referred to ...
(Date:11/27/2015)... NC (PRWEB) , ... November 27, 2015 , ... A ... effective ways to treat it. Surviving Mesothelioma has just posted the findings on ... at University Hospital Zurich analyzed the cases of 136 mesothelioma patients who were treated ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... edition of USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, with ... digital component is distributed nationally, through a vast social media strategy and across ...
(Date:11/27/2015)... ... November 27, 2015 , ... Intellitec Solutions ... SL User Group (MSDSLUG). Recognized as Microsoft’s official group for end users of ... SL software users, partners, industry experts and representatives. Intellitec Solutions’ membership status demonstrates ...
(Date:11/27/2015)... ... November 27, 2015 , ... CBD College is proud to announce ... (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography program. CBD College is honored to ... of twelve colleges and universities in the state of California make the cut. CBD ...
Breaking Medicine News(10 mins):